To discuss the limitations of current pre-eclampsia testing and the potential of PlGF testing to improve care.
Approach:
Current Standard of Care: The standard relies on clinical signs like elevated blood pressure and proteinuria, which indicate disease progression.
PlGF Testing Benefits: PlGF testing provides early biological signals of placental health, allowing for better risk stratification and decision-making.
NICE Recommendations: NICE recommended PlGF testing for suspected pre-eclampsia in 2016, updated in 2022, showing a commitment to evidence-based care.
Implementation Challenges: Adoption of PlGF testing varies regionally, with barriers related to operational integration, awareness, and clinical inertia.
Future Directions: Health systems should integrate PlGF testing into triage protocols and invest in training to improve consistency and equity in care.
Key Findings:
Pre-eclampsia affects 1 in 25 pregnancies in the UK and is a leading cause of maternal and perinatal mortality.
Current testing methods often fail to identify at-risk patients early.
PlGF testing can reduce time to diagnosis and improve clinical decision-making.
There are significant regional variations in the implementation of PlGF testing despite NICE recommendations.
Interpretation:
Limitations:
Operational and cultural barriers hinder the integration of PlGF testing into clinical workflows.
There is a need for increased awareness and training among healthcare providers.
Ahead of ISC2026 in Prague, Jennifer Van Eyk explains how scalable LC-MS workflows and single-cell proteomics are helping reveal the biological differences that could make precision medicine a clinical reality
